ZIOPHARM Oncology to Present at the 25th Annual Piper Jaffray Healthcare Conference

ZIOPHARM Oncology to Present at the 25th Annual Piper Jaffray Healthcare

BOSTON, Nov. 27, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc.
(Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief
Executive Officer, will present at the 25th Annual Piper Jaffray Healthcare
Conference on Tuesday, December 3rd, 2013 at 10:30 a.m. ET at The New York
Palace Hotel in New York City.

To access a live audio webcast of the presentation, please visit the Investor
Relations section at www.ziopharm.com. The webcast will be archived for 90

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company
employing novel gene expression and control technology to deliver DNA for the
treatment of cancer. ZIOPHARM's technology platform employs Intrexon
Corporation's RheoSwitch Therapeutic System® to turn on and off, and precisely
modulate, gene expression at the cancer site in order to improve the
therapeutic index. This technology is currently being evaluated in Phase 2
clinical studies of the immune system cytokine interleukin-12 for the
treatment of breast cancer and advanced melanoma. Multiple new Investigational
New Drug applications for new targets using similar technology are expected in
2014 and 2015. ZIOPHARM is also developing novel small molecules as potential
cancer therapeutics.

Forward-Looking Safe Harbor Statement:

This press release contains certain forward-looking information about ZIOPHARM
Oncology, Inc. that is intended to be covered by the safe harbor for
"forward-looking statements" provided by the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"
"will," "may," "anticipate(s)" and similar expressions are intended to
identify forward-looking statements. These statements include, but are not
limited to, statements regarding our ability to successfully develop and
commercialize our therapeutic products; our ability to expand our long-term
business opportunities; financial projections and estimates and their
underlying assumptions; and future performance. All of such statements are
subject to certain risks and uncertainties, many of which are difficult to
predict and generally beyond the control of the Company, that could cause
actual results to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include, but are not limited to: whether palifosfamide,
Ad-RTS-IL-12, darinaparsin, indibulin, or any of our other therapeutic
products will advance further in the clinical trials process and whether and
when, if at all, they will receive final approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and for which
indications; whether palifosfamide, Ad-RTS-IL-12, darinaparsin, indibulin, and
our other therapeutic products will be successfully marketed if approved;
whether any of our other therapeutic product discovery and development efforts
will be successful; our ability to achieve the results contemplated by our
collaboration agreements; the strength and enforceability of our intellectual
property rights; competition from other pharmaceutical and biotechnology
companies; the development of, and our ability to take advantage of, the
market for our therapeutic products; our ability to raise additional capital
to fund our operations on terms acceptable to us; general economic conditions;
and the other risk factors contained in our periodic and interim SEC reports
filed from time to time with the Securities and Exchange Commission, including
but not limited to, our Annual Report on Form 10-K for the fiscal year ended
December 31, 2012, and our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2013. Readers are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof, and we do
not undertake any obligation to revise and disseminate forward-looking
statements to reflect events or circumstances after the date hereof, or to
reflect the occurrence of or non-occurrence of any events.

CONTACT: For ZIOPHARM Investor Relations:
         David Pitts
         Argot Partners
         Media Contacts:
         David Schull or Lena Evans
         Russo Partners, LLC

ZIOPHARM Oncology, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.